SecBot SecBot
SECBOTREPLAY Home › Report › LAB

LAB · Standard Biotools (LAB) files S-4 for its all-stock merger with private…

STANDARD BIOTOOLS INC. · S-4 filed Jul 20, 2026 at 06:45 ET

At the news

MIXEDIMPACT 7/10

S-4 filed Jul 20, 2026 at 06:45 ET

Standard Biotools (LAB) files S-4 for its all-stock merger with private biotech Treeline Biosciences, valuing Treeline at $2.5B and LAB at $460M. LAB shareholders will own ~16% of the combined company, which will focus on Treeline's clinical-stage oncology pipeline with ~$1.06B in pro forma cash. The filing also includes a CVR tied to monetization of LAB's legacy businesses, up to 76M shares. The merger requires LAB shareholder approval and is expected to close in H2 2026.

  • Treeline valued at $2.5B, LAB at $460M; combined pro forma cash ~$1.06B
  • LAB shareholders to own ~16% of combined company on a fully diluted basis
  • Treeline has three Phase 1 programs (TLN-121, TLN-254, TLN-372) and a fourth nearing clinical entry (TLN-499)
  • TLN-254 (EZH2 inhibitor) under partial clinical hold due to class-wide safety concerns with tazemetostat

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access